To understand whether our BRAF-mutant cell lines were biologically relevant for evaluating resistance in human gliomas, we first sought to clarify the lines’ dependence on oncogenic BRAF V600E versus exogenous growth factors for RAF-ERK signaling. The gene discussed is RAF1; the disease is central nervous system cancer.